Selected publications Leonid Padyukov
Genetic markers for the efficacy of TNF blocking therapy in rheumatoid arthritis L. Padyukov, J. Lampa, M. Heimbürger, S. Ernestam, T. Cederholm, I. Lundkvist, P. Andersson, Y. Hermansson, A. Harju, L. Klareskog, J. Bratt. Ann Rheum Disease, 2003, 62: 526-529.
A gene-environment interaction between smoking and shared epitope genes in HLA-DRB1 provides a high risk of seropositive rheumatoid arthritis, L Padyukov, C Silva, P Stolt, L Alfredsson, L Klareskog, The EIRA study group, Arthritis & Rheumatism, 2004, 50, 10: 3085-3092.
Common variations in the IL-4R gene affect splicing and influence natural expression of the soluble isoform Bergin AM, Balder B, Kishore S, Swärd K, Hahn-Zoric M, Löwhagen O, Hanson LA, Padyukov L. Human Mutation, 2006, 27(10): 990-998.
TRAF1–C5 as a Risk Locus for Rheumatoid Arthritis — A Genomewide Study, RM. Plenge, M Seielstad, L Padyukov, A T. Lee, EF Remmers, B Ding, A Liew, H Khalili A Chandrasekaran, LRL Davies, W Li, AKS Tan, C Bonnard, RTH Ong, A Thalamuthu, S Pettersson, C Liu, C Tian, WV Chen, JP Carulli, D Altshuler, L Alfredsson, LA Criswell, CI Amos, MF Seldin, DL Kastner, L Klareskog, PK Gregersen NEJM, 2007, 357(12):1199-1209.
Evidence for interaction between 5-hydroxytryptamine (serotonin) receptor 2A and MHC type 2 molecules in development of rheumatoid arthritis. Seddighzadeh M, Korotkova M, Källberg H, Ding B, Daha N, Kurreeman FA, Toes RE, Huizinga TW, Catrina AI, Alfredsson L, Klareskog L, Padyukov L. Eur J Hum Genet. 2010 Jul;18(7):821-6